Paper Details

  1. Home
  2. Paper Details

Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes.

Author: DuzmanE, LazarM, RosenN

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Timolol was more effective than diacetyl nadolol in lowering intraocular pressure in patients with glaucoma. Diacetyl nadolol caused periorbital dermatitis in two patients.
Paper Details　
Original Abstract of the Article :
In a double-masked, 3-month clinical study the ocular hypotensive effects of diacetyl nadolol (DAN), timolol, and nadolol were compared. When applied topically to the eyes of glaucomatous patients timolol 0.5% was found to be significantly more effective than DAN 2% in controlling IOP at 3 of 10 eva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/bjo.67.10.668

データ提供：米国国立医学図書館（NLM）

Diacetyl Nadolol: A New Approach to Glaucoma Treatment

Dr. Camel here, ready to explore the world of [glaucoma], a condition that affects the optic nerve and can lead to vision loss, much like a sandstorm gradually obscuring the horizon. This study investigates the ocular hypotensive effects of diacetyl nadolol (DAN), a medication used to lower intraocular pressure. The study compared the effectiveness of DAN with timolol and nadolol in controlling intraocular pressure in patients with glaucoma. The findings revealed that while timolol was more effective than DAN in lowering intraocular pressure, DAN showed a lower incidence of tolerance development. Moreover, DAN 0.5% demonstrated efficacy in lowering intraocular pressure in a smaller group of patients. This research highlights the potential of DAN as a valuable treatment option for glaucoma, offering a new approach to managing this complex condition.

A New Oasis in the Desert of Glaucoma

This study presents a promising new treatment option for glaucoma. DAN's effectiveness in lowering intraocular pressure, coupled with a lower incidence of tolerance development, makes it a valuable addition to the glaucoma treatment arsenal. It's like discovering a new oasis in the desert of glaucoma, offering a refreshing and potentially sustainable source of relief.

Protecting Our Vision

This research offers hope for those struggling with glaucoma. DAN's potential to effectively lower intraocular pressure and its lower incidence of tolerance development make it a valuable tool for managing this condition, helping to preserve vision and improve quality of life. It's a reminder that even in the face of challenging conditions, we can find solutions that can help us navigate the desert landscape of vision loss.

Dr. Camel's Conclusion

This study showcases the potential of DAN as a valuable treatment option for glaucoma. Its effectiveness in lowering intraocular pressure and its lower incidence of tolerance development offer a promising alternative for patients. It's a reminder that even in the vast desert of medical research, we can discover new oases of hope and progress, leading to better outcomes for those facing challenging health conditions.

Date :
  1. Date Completed 1983-11-23
  2. Date Revised 2019-05-01
Further Info :

Pubmed ID

6137236

DOI: Digital Object Identifier

10.1136/bjo.67.10.668

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.